Summary of "Nuclear medicine physics and applications"

Overview

Nuclear medicine (including PET‑CT) uses radiopharmaceuticals — radioactive isotopes attached to biologically active molecules — to image physiological and biochemical processes, make diagnoses, and deliver therapy. It differs from conventional imaging (X‑ray, CT) because the patient becomes the source of radiation; emitted radiation is detected rather than produced externally.

The talk covered:

Basic physics (isotopes, decay, emissions)
How scans are acquired
Common radiopharmaceuticals and clinical uses
PET‑CT principles
Radiation safety and regulatory implications
Typical clinical applications, particularly cancer staging and treatment monitoring

Key concepts and definitions

Radiopharmaceutical: a biologically active compound labeled with a radioactive isotope to target a physiological process.
Radioisotope (radioactive isotope): an unstable isotope that decays to a more stable state and emits radiation (alpha, beta, positron, gamma).
Activity and unit: activity = disintegrations per second; SI unit is the becquerel (Bq).
Half‑life: time for half the radioactive nuclei to decay; decay is exponential.
Effective half‑life: depends on both physical decay and biological clearance; governs how long patients/items remain radioactive.

Dose examples (approximate figures given in the lecture):

UK background radiation: ~2–2.6 mSv/year
Chest X‑ray: ~0.1 mSv
CT head (lecture figure): ~2 mSv
CT thorax: ~4–5 mSv
Whole‑body technetium bone scan (~600 MBq): ~3 mSv
PET scan: up to ~8 mSv

Common emissions:

Gamma photons — primary useful emission for conventional nuclear imaging.
Positrons — emitted by PET tracers; annihilation with electrons produces two 511 keV photons detected in coincidence.
Alpha/beta — used therapeutically and in some production pathways (beta emitters used in some therapies and isotope production).

How a conventional nuclear medicine scan is acquired (stepwise)

Radiopharmaceutical is manufactured in a radiopharmacy (sealed, radiation‑safe environment).
Administer to the patient (IV injection, inhalation, oral/ingestion, or mixed with food depending on the agent).
Allow biodistribution/time for the tracer to localize to the target tissue.
Place the patient in a gamma camera (one or more detectors) to detect emitted gamma photons over a specified acquisition time (often 30–60 minutes or longer depending on the study).
Reconstruct detected events into images showing distribution of tracer (a functional/physiological map).
Correlate with anatomical imaging (CT, MRI) when required.

How PET‑CT works (principles and stepwise)

PET tracers are positron emitters (e.g., F‑18).
A positron emitted by the isotope annihilates with an electron, producing two 511 keV photons travelling in opposite directions.
A detector ring records coincident photon pairs (lines of response) and, after many events, builds a 3D map of tracer distribution.
PET acquisition is followed by CT on the same scanner; images are fused so functional PET data are combined with anatomical CT for improved localization and interpretation.

Practical examples of radiopharmaceuticals and their uses

Technetium‑99m (Tc‑99m; half‑life ~6 hours) — the most commonly used radionuclide for conventional nuclear studies; can be labeled to different compounds:

HDP/MDP (technetium‑labeled phosphate): bone scan to detect osteoblastic activity — sensitive for bone metastases (not always specific; fractures/degeneration also give uptake).
DMSA: renal cortical imaging (scarring, differential function).
MAA (macroaggregated albumin) with Tc‑99m: perfusion component of V/Q scan for pulmonary embolism (sensitive, lower dose than CTPA).
Sestamibi (Tc‑99m): myocardial perfusion imaging (rest/stress) to detect ischemia.
HMPAO (Tc‑99m): brain perfusion/metabolic imaging (patterns in neurodegenerative disease).
Parathyroid scintigraphy: identify parathyroid adenomas.

Other conventional tracers:

Indium‑111, iodine isotopes, gallium — used for specific imaging or therapy (e.g., I‑123 for thyroid imaging; I‑131 for therapy).

PET tracers:

Fluorine‑18 FDG (F‑18 FDG; half‑life ~110 minutes): glucose analogue taken up by metabolically active cells; widely used in oncology, infection/inflammation, some neurology and cardiology applications.

Theranostics:

Combined approach using different isotopes for imaging and therapy (example: Ga‑68 or In‑111 for somatostatin receptor imaging and Lu‑177 or I‑131 for targeted therapy).

Basic isotope production and generator concept

Tc‑99m is commonly obtained from a molybdenum‑99 (Mo‑99) generator: Mo‑99 decays to Tc‑99m; the generator is eluted (saline passed through) to collect Tc‑99m for labeling kits.
Generator output declines over the week as Mo‑99 decays, affecting scheduling and available activity.

Radiation safety, timing and logistics

Patients remain radioactive after administration until tracer decays or is excreted. This requires special infection‑control/cleanup procedures (e.g., “hot toilets”), handling of contaminated clothes/linen, and restrictions on close contact with family and staff.
Timing matters:
- Decay between preparation and injection changes administered activity.
- Interventional procedures or surgery immediately after nuclear imaging require consideration of residual activity; delays may be needed to limit staff dose depending on isotope half‑life and activity.
Use half‑life calculations to estimate how long items/patients remain significantly radioactive (e.g., Tc‑99m halves every 6 hours; F‑18 halves every ~110 minutes).
Nuclear medicine examinations can deliver relatively high doses; they are regulated and require appropriate authorizations and local committee oversight.
Effective half‑life and biological clearance both affect residual activity, not just physical half‑life.

Clinical strengths, limitations and typical applications

Strengths:

Functional/physiological imaging often detects disease earlier than morphology alone.
Whole‑body surveys (e.g., bone scan, PET) identify sites distant from the primary lesion.
PET‑CT improves staging accuracy, assesses treatment response (metabolic changes often precede size reduction), guides biopsy targeting, and helps solve diagnostic problems (occult primary, infection/inflammation, differentiating radiation necrosis vs tumor).

Limitations:

Many nuclear tests are sensitive but not highly specific — uptake can reflect benign causes (inflammation, infection, fracture, degenerative change).
Correlation with anatomical imaging (CT/MRI) and the clinical context is essential.

Key PET‑CT indications (summary):

Staging cancers amenable to curative treatment
Characterization of indeterminate lesions
Response assessment to therapy (e.g., lymphoma)
Detecting recurrence/residual disease
Guiding biopsy (choose metabolically active region)
Identifying occult primary tumors
Locating infection or inflammation (fever of unknown origin, vasculitis)
Detecting malignant transformation

Illustrative clinical examples

Bone scan: Tc‑99m‑labeled phosphate detects osteoblastic activity; whole‑body bone scans are used for prostate and breast cancer metastases. Hot spots indicate increased osteoblastic activity but require CT correlation for specificity.
FDG PET‑CT (lung cancer): can identify a primary lung lesion and mediastinal nodal disease that CT alone might miss, potentially changing management (surgery vs systemic therapy).
PET for infection/inflammation: FDG PET can detect large‑vessel vasculitis (e.g., Takayasu) when other tests are negative.

Takeaway lessons

Nuclear medicine and PET‑CT provide functional information that complements anatomical imaging; they are indispensable in oncology, selected cardiac, renal and neurodegenerative indications, and in infection/inflammation workups.
Understanding isotope physics (emission type, half‑life), radiopharmaceutical biology (targeting), imaging acquisition, and radiation safety is crucial for appropriate use and interpretation.
Because the patient is the radiation source, procedural timing, safety protocols, and clear communication about distancing, excretion, and contamination are essential.

Speakers and sources

Speaker: Dr Anva Camille — Consultant Nuclear Medicine Radiologist, University Hospitals of Leicester.
Organizations referenced:
- University Hospitals of Leicester
- Royal College of Physicians and Radiologists (document on PET‑CT indications referenced)
- RSAC committee (regulatory body mentioned in context of scan authorization)